A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Excluded: MET exon 14 skipping

patients with MET 14 exon skipping detected by gene sequencing report before signing informed consent [excluded for stage 3 Cohort_A]

Cannot have received: chemotherapy

Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose

Cannot have received: biological therapy

Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose

Cannot have received: mitomycin (mitomycin)

Mitomycin and nitrosoureas were administered within 6 weeks before the first dose

Cannot have received: nitrosourea (nitrosoureas)

Mitomycin and nitrosoureas were administered within 6 weeks before the first dose

Cannot have received: oral antimetabolite (fluorouracil)

Oral drugs such as fluorouracil

Cannot have received: immunotherapy

Exception: if developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis

Had received immunotherapy and developed ≥ grade 3 irAE or ≥ grade 2 immune-related myocarditis

Cannot have received: immunomodulatory drug

Use of immunomodulatory drugs within 14 days before the first dose of study drug